Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-269680
Filing Date
2025-11-06
Accepted
2025-11-06 16:26:55
Documents
70
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-20250930.htm   iXBRL 10-Q 3029216
2 EX-31.1 ntla-ex31_1.htm EX-31.1 15109
3 EX-31.2 ntla-ex31_2.htm EX-31.2 15129
4 EX-32.1 ntla-ex32_1.htm EX-32.1 9974
  Complete submission text file 0001193125-25-269680.txt   10747995

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ntla-20250930.xsd EX-101.SCH 1303160
73 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20250930_htm.xml XML 1980033
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 251458821
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)